SAN DIEGO, May 22, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that two abstracts have been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), being held in Montreal, Canada and virtually on June 24-28, 2023.
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.